<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697655</url>
  </required_header>
  <id_info>
    <org_study_id>PMC008</org_study_id>
    <nct_id>NCT03697655</nct_id>
  </id_info>
  <brief_title>Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma</brief_title>
  <acronym>PREDATOR</acronym>
  <official_title>Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Myeloma Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioscience, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Myeloma Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical&#xD;
      relapse or progression of multiple myeloma (MM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is composed of two phase 2 randomized multi-center substudies:&#xD;
&#xD;
        -  PREDATOR-BR: to investigate the role of daratumumab in the setting of biochemical&#xD;
           relapse&#xD;
&#xD;
        -  PREDATOR-MRD: to investigate the role of daratumumab in minimal residual disease (MRD)&#xD;
           reappearance&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>treatment arm and control (observation) arm</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (ESF)</measure>
    <time_frame>from randomization till the date of development clinical relapse or death from any cause; up to 129 weeks</time_frame>
    <description>To compare (EFS) between daratumumab arm and observation arm after randomization of patients with biochemical relapse of Multiple Myeloma and MRD reappearance in Multiple Myeloma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from randomization till progression or death from any cause, up to 129 weeks</time_frame>
    <description>ORR as determined by Investigator evaluation, defined as the percentage of subjects achieving an objective response (i.e. partial response or better), using IMWG Consensus Panel 1 response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>throughout the duration of the study, no longer than 6 years</time_frame>
    <description>To compare overall survival between arms</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PREDATOR-BR Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREDATOR-BR Cohort B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>n=46, Control Group, Observation (no treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREDATOR-MRD Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREDATOR-MRD Cohort B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>n=59, Control Group, Observation (no treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab 20 MG/ML [Darzalex]</intervention_name>
    <description>Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks</description>
    <arm_group_label>PREDATOR-BR Cohort A</arm_group_label>
    <arm_group_label>PREDATOR-MRD Cohort A</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PREDATOR-BR:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with diagnosed symptomatic MM who have completed one or two prior lines of&#xD;
             therapy; single or tandem autologous stem cell transplant is not considered a separate&#xD;
             line of therapy and is not mandatory; and have achieved at least PR to last line of&#xD;
             therapy, and who experience asymptomatic biochemical progression not meeting criteria&#xD;
             for SPR.&#xD;
&#xD;
          2. Males and females ≥18 years of age.&#xD;
&#xD;
          3. Life expectancy of more than 3 months.&#xD;
&#xD;
          4. ECOG performance status of 0-2.&#xD;
&#xD;
          5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase&#xD;
             (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.&#xD;
&#xD;
          6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.&#xD;
&#xD;
          7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as&#xD;
             follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma&#xD;
             creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.&#xD;
&#xD;
          8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including&#xD;
             pre-menopausal women who have had a tubal ligation) and for all women not meeting the&#xD;
             definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone&#xD;
             surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all&#xD;
             other women, documentation must be present in medical history confirming that the&#xD;
             patient is not of childbearing potential.&#xD;
&#xD;
          9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice&#xD;
             complete abstinence from heterosexual intercourse during the study.&#xD;
&#xD;
         10. Male subjects must agree to use a latex condom during sexual contact with females of&#xD;
             childbearing potential while participating in the study and for at least 28 days&#xD;
             following discontinuation from the study even if he has undergone a successful&#xD;
             vasectomy.&#xD;
&#xD;
         11. Voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG&#xD;
             criteria.&#xD;
&#xD;
          2. Patient with SPR - significant paraprotein relapse defined as doubling of the&#xD;
             M-component in two consecutive measurements separated by &lt; 2 months; or an increase in&#xD;
             the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or&#xD;
             involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive&#xD;
             measurements separated by &lt; 2 months.&#xD;
&#xD;
          3. Patients who have already started or received post-transplant maintenance or&#xD;
             consolidation treatment.&#xD;
&#xD;
          4. Subject has received daratumumab or other anti-CD38 therapies previously.&#xD;
&#xD;
          5. Patients not able to tolerate daratumumab or required concomitant medication and&#xD;
             procedures.&#xD;
&#xD;
          6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in&#xD;
             1 second (FEV1) &lt;50% of predicted normal. Note that FEV1 testing is required for&#xD;
             subjects suspected of having COPD and subjects must be excluded if FEV1 &lt;50% of&#xD;
             predicted normal.&#xD;
&#xD;
          7. Known moderate or severe persistent asthma, or a history of asthma within the last 2&#xD;
             years, or currently has uncontrolled asthma of any classification. (Note that subjects&#xD;
             who currently have controlled intermittent asthma or controlled mild persistent asthma&#xD;
             are allowed to participate in the study).&#xD;
&#xD;
          8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes).&#xD;
&#xD;
          9. Plasma cell leukemia.&#xD;
&#xD;
         10. Waldenström's macroglobulinemia.&#xD;
&#xD;
         11. CNS involvement.&#xD;
&#xD;
         12. Pregnant or lactating females.&#xD;
&#xD;
         13. Radiotherapy within 14 days before randomization. Seven days may be considered if to&#xD;
             single area.&#xD;
&#xD;
         14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a&#xD;
             major surgery.&#xD;
&#xD;
         15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart&#xD;
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or&#xD;
             electrocardiographic evidence of acute ischemia or active conduction system&#xD;
             abnormalities.&#xD;
&#xD;
         16. Rate-corrected QT interval of electrocardiograph (QTc) &gt; 470 msec on a 12-lead ECG&#xD;
             during screening.&#xD;
&#xD;
         17. Patient who in investigator's opinion is unable to comply with the protocol&#xD;
             requirements.&#xD;
&#xD;
         18. Uncontrolled hypertension or diabetes.&#xD;
&#xD;
         19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two&#xD;
             weeks prior to enter the study.&#xD;
&#xD;
         20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus&#xD;
             (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B&#xD;
             virus vaccine are eligible.&#xD;
&#xD;
         21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3&#xD;
             years except a) adequately treated basal cell, squamous cell skin cancer, thyroid&#xD;
             cancer, carcinoma in situ of the cervix, or prostate cancer &lt; Gleason Grade 6 with&#xD;
             stable prostate specific antigen levels or cancer considered cured by surgical&#xD;
             resection alone.&#xD;
&#xD;
         22. Any clinically significant medical disease or condition that, in the Investigator's&#xD;
             opinion, may interfere with protocol adherence or a subject's ability to give informed&#xD;
             consent.&#xD;
&#xD;
        PREDATOR-MRD:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with diagnosed symptomatic MM who have completed one or two prior lines of&#xD;
             therapy; single or tandem autologous stem cell transplant is not considered a separate&#xD;
             line of therapy and is not mandatory; and have achieved CR with negative MRD to the&#xD;
             last line of therapy and who remain in CR MRD negative. The last response assessment&#xD;
             confirming CR MRD negative status based on assessment of bone marrow sample using flow&#xD;
             cytometry with sensitivity of at least 10-5 needs to be performed not earlier than 3&#xD;
             months before inclusion to the study.&#xD;
&#xD;
          2. Males and females ≥18 years of age.&#xD;
&#xD;
          3. Life expectancy of more than 3 months.&#xD;
&#xD;
          4. ECOG performance status of 0-2.&#xD;
&#xD;
          5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase&#xD;
             (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.&#xD;
&#xD;
          6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.&#xD;
&#xD;
          7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as&#xD;
             follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma&#xD;
             creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.&#xD;
&#xD;
          8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including&#xD;
             pre-menopausal women who have had a tubal ligation) and for all women not meeting the&#xD;
             definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone&#xD;
             surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all&#xD;
             other women, documentation must be present in medical history confirming that the&#xD;
             patient is not of childbearing potential&#xD;
&#xD;
          9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice&#xD;
             complete abstinence from heterosexual intercourse during the study.&#xD;
&#xD;
         10. Male subjects must agree to use a latex condom during sexual contact with females of&#xD;
             childbearing potential while participating in the study and for at least 28 days&#xD;
             following discontinuation from the study even if he has undergone a successful&#xD;
             vasectomy.&#xD;
&#xD;
         11. Voluntary written informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG&#xD;
             criteria.&#xD;
&#xD;
          2. Patient with SPR - significant paraprotein relapse defined as doubling of the&#xD;
             M-component in two consecutive measurements separated by &lt; 2 months; or an increase in&#xD;
             the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or&#xD;
             involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive&#xD;
             measurements separated by &lt; 2 months.&#xD;
&#xD;
          3. Patients who have already started or received post-transplant maintenance or&#xD;
             consolidation treatment.&#xD;
&#xD;
          4. Subject has received daratumumab or other anti-CD38 therapies previously.&#xD;
&#xD;
          5. Patients not able to tolerate daratumumab or required concomitant medication and&#xD;
             procedures.&#xD;
&#xD;
          6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in&#xD;
             1 second (FEV1) &lt;50% of predicted normal. Note that FEV1 testing is required for&#xD;
             subjects suspected of having COPD and subjects must be excluded if FEV1 &lt;50% of&#xD;
             predicted normal.&#xD;
&#xD;
          7. Known moderate or severe persistent asthma, or a history of asthma within the last 2&#xD;
             years, or currently has uncontrolled asthma of any classification. (Note that subjects&#xD;
             who currently have controlled intermittent asthma or controlled mild persistent asthma&#xD;
             are allowed to participate in the study).&#xD;
&#xD;
          8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes).&#xD;
&#xD;
          9. Plasma cell leukemia.&#xD;
&#xD;
         10. Waldenström's macroglobulinemia.&#xD;
&#xD;
         11. CNS involvement.&#xD;
&#xD;
         12. Pregnant or lactating females.&#xD;
&#xD;
         13. Radiotherapy within 14 days before randomization. Seven days may be considered if to&#xD;
             single area.&#xD;
&#xD;
         14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a&#xD;
             major surgery.&#xD;
&#xD;
         15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart&#xD;
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or&#xD;
             electrocardiographic evidence of acute ischemia or active conduction system&#xD;
             abnormalities.&#xD;
&#xD;
         16. Rate-corrected QT interval of electrocardiograph (QTc) &gt; 470 msec on a 12- lead ECG&#xD;
             during screening.&#xD;
&#xD;
         17. Patient who in investigator's opinion is unable to comply with the protocol&#xD;
             requirements.&#xD;
&#xD;
         18. Uncontrolled hypertension or diabetes.&#xD;
&#xD;
         19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two&#xD;
             weeks prior to enter the study.&#xD;
&#xD;
         20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus&#xD;
             (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B&#xD;
             virus vaccine are eligible.&#xD;
&#xD;
         21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3&#xD;
             years except a) adequately treated basal cell, squamous cell skin cancer, thyroid&#xD;
             cancer, carcinoma in situ of the cervix, or prostate cancer &lt; Gleason Grade 6 with&#xD;
             stable prostate specific antigen levels or cancer considered cured by surgical&#xD;
             resection alone.&#xD;
&#xD;
         22. Any clinically significant medical disease or condition that, in the Investigator's&#xD;
             opinion, may interfere with protocol adherence or a subject's ability to give informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krzysztof Jamroziak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polish Myeloma Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krzysztof Jamroziak, MD, PhD</last_name>
    <phone>+48 504 065 262</phone>
    <email>k.m.jamroziak@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominik Dytfeld, MD, PhD</last_name>
    <phone>+48 602 464 708</phone>
    <email>dytfeld@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Jamroziak, MD, PhD</last_name>
      <phone>+48 22 349 64 78</phone>
      <email>k.m.jamroziak@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; Oddział Hematologii i Transplantacji Szpiku</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Dytfeld, MD, PhD</last_name>
      <phone>+48 602464708</phone>
      <email>dytfeld@me.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

